Sinopharm Group (01093): Selective 5-HT2A receptor agonist approved for clinical trials in the United States.

Zhtng Cijng APP news, Sh Yo Jtun (01093) fb gnggo, jtun kif de huyo 1 li xnyo xunzxng 5-Husrn 2A shut (5-HT2A shut) jdngj (SYH2056 pin) (gi chnpn) y hud migu shpn yopn jind gunl j pzhn, k zi migu kizhn lnghun shyn. Gi chnpn y y y 2025 nin 11 yu hud zhnghu rnmn gnghgu guji yopn jind gunl j pzhn zi zhnggu kizhn lnghun shyn. Zhtng Cijng APP news, Sh Yao Group (01093) issued an announcement that the group's new drug development of selective 5-hydroxytryptamine 2A receptor (5-HT2A receptor) agonist (SYH2056 tablets) has been approved by the U.S. Food and Drug Administration for clinical trials in the United States. The product has also been approved by the National Medical Products Administration of the People's Republic of China for clinical trials in China in November 2025.